Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

 

Publications des scientifiques de l'IRD

Cressey T. R., Punyawudho B., Le Coeur S., Jourdain Gonzague, Saenjum C., Capparelli E. V., Jittayanun K., Phanomcheong S., Luvira A., Borkird T., Puangsombat A., Aarons L., Sukrakanchana P. O., Urien S., Lallemant Marc, Phpt-5 Study Team (collab.). (2017). Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates. JAIDS - Journal of Acquired Immune Deficiency Syndromes, 75 (5), 554-560. ISSN 1525-4135

Accès réservé (Intranet IRD) Demander le PDF

Titre
Assessment of nevirapine prophylactic and therapeutic dosing regimens for neonates
Année de publication2017
Type de documentArticle référencé dans le Web of Science WOS:000405556900009
AuteursCressey T. R., Punyawudho B., Le Coeur S., Jourdain Gonzague, Saenjum C., Capparelli E. V., Jittayanun K., Phanomcheong S., Luvira A., Borkird T., Puangsombat A., Aarons L., Sukrakanchana P. O., Urien S., Lallemant Marc, Phpt-5 Study Team (collab.).
SourceJAIDS - Journal of Acquired Immune Deficiency Syndromes, 2017, 75 (5), p. 554-560. ISSN 1525-4135
RésuméBackground: Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates. We evaluated current World Health Organization (WHO) weight-band NVP prophylactic dosing recommendations and investigated optimal therapeutic NVP dosing for neonates. Methods: The PHPT-5 study in Thailand assessed the efficacy of "Perinatal Antiretroviral Intensification" to prevent mother-to-child transmission of HIV in women with <8 weeks of antiretroviral treatment before delivery (NCT01511237). Infants received a 2-week course of zidovudine/lamivudine/NVP (NVP syrup/once daily: 2 mg/kg for 7 days; then 4 mg/kg for 7 days). Infant samples were assessed during the first 2 weeks of life. NVP population pharmacokinetics (PK) parameters were estimated using nonlinear mixed-effects models. Simulations were performed to estimate the probability of achieving target NVP trough concentrations for prophylaxis (>0.10 mg/L) and for therapeutic efficacy (>3.0 mg/L) using different infant dosing strategies. Results: Sixty infants (55% male) were included. At birth, median (range) weight was 2.9 (2.3-3.6) kg. NVP concentrations were best described by a 1-compartment PK model. Infant weight and postnatal age influenced NVP PK parameters. Based on simulations for a 3-kg infant, >= 92% would have an NVP trough >0.1 mg/L after 48 hours through 2 weeks using the PHPT-5 and WHO-dosing regimens. For NVP-based therapy, a 6-mg/kg twice daily dose produced a trough >3.0 mg/L in 87% of infants at 48 hours and 80% at 2 weeks. Conclusion: WHO weight-band prophylactic guidelines achieved target concentrations. Starting NVP 6 mg/kg twice daily from birth is expected to achieve therapeutic concentrations during the first 2 weeks of life.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Santé : généralités [050]
Descr. géo.THAILANDE
LocalisationFonds IRD [F B010070375]
Identifiant IRDfdi:010070375
Lien permanenthttp://www.documentation.ird.fr/hor/fdi:010070375

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Cayenne

Nouméa

Papeete

Abidjan

Dakar

Niamey

Ouagadougou

Tunis

La Paz

Quito